
Compartir
Título
Specific Glutamylation Patterns of the Cytoskeleton Confer Neuroresistance to Lobe X of the Cerebellum in a Model of Childhood-Onset Neurodegeneration with Cerebellar Atrophy
Autor(es)
Palabras clave
CCP
cerebellum
CONDCA
glutamylation
Purkinje cell degeneration
neuroprotection
Clasificación UNESCO
3205.07 Neurología
Fecha de publicación
2025
Editor
MDPI
Citación
Hernández-Pérez, C.; Calderón-García, A.A.; Pérez-Boyero, D.; González-Núñez, V.; Weruaga, E.; Díaz, D. Specific Glutamylation Patterns of the Cytoskeleton Confer Neuroresistance to Lobe X of the Cerebellum in a Model of Childhood-Onset Neurodegeneration with Cerebellar Atrophy. Int. J. Mol. Sci. 2025, 26, 10378. https://doi.org/ 10.3390/ijms262110378
Resumen
[EN]The cytoskeleton relies heavily on the dynamic nature of microtubules, regulated by posttranslational
modifications such as polyglutamylation and deglutamylation. Disruption
of its internal balance, particularly through the absence of cytosolic carboxypeptidase
1 (CCP1), leads to cytoskeletal collapse and cell death. An example of this occurrence exists
in the Purkinje Cell Degeneration (PCD) mouse, a direct animal model for childhood-onset
neurodegeneration with cerebellar atrophy (CONDCA) human disease. Both CONDCA
patients and PCD mice suffer a dramatic degeneration of Purkinje cells. Intriguingly, lobe
X appears less vulnerable to this insult. This study revealed in wild-type mice that lobe X
expresses less Ccp1 compared to other lobes, correlating with its delayed degeneration in
PCD mice. Further expression analysis of other deglutamylating enzymes (CCP4 and CCP6)
and glutamylating enzymes (TTLL1) revealed distinctive patterns: Ccp4 showed minimal
relevance in cerebellum, while Ccp6 displayed a compensatory increase during critical
stages. Meanwhile, Ttll1 expression remained consistent across lobes, suggesting that the
resistance of lobe X may be related to a more dynamic, hyperglutamylated cytoskeleton.
Unraveling the neuroresistance mechanisms of Purkinje cells may help mitigate neuronal
loss in CONDCA patients and may offer a glimmer of hope for alleviating the symptoms
of other neurodegenerative diseases.
URI
DOI
10.3390/ijms262110378
Versión del editor
Aparece en las colecciones
Fichier(s) constituant ce document
Nombre:
Tamaño:
8.156Mo
Formato:
Adobe PDF
Descripción:
Artículo principal más datos suplementarios













